Silver Book

Silver Book Fact

Flu causes close to 1/2 of lost workdays and low productivity in adults 50-64 during flu season

During influenza season, influenza-like-illness is responsible for 45% of workdays lost and for 49% of low productivity days among working adults aged 50–64 years.

Nichol K, D'Heilly S, Greenberg M, Ehlinger E, et al. Burden of Influenza-like Illness and Effectiveness of Influenza Vaccination Among Working Adults Aged 50-64 Years. Clin Infect Dis. 2009; 48(3): 292-8. http://cid.oxfordjournals.org/content/48/3/292.long

Reference

Title
Burden of Influenza-like Illness and Effectiveness of Influenza Vaccination Among Working Adults Aged 50-64 Years
Publication
Clin Infect Dis
Publication Date
2009
Authors
Nichol K, D'Heilly S, Greenberg M, Ehlinger E, et al.
Volume & Issue
Volume 48, Issue 3
Pages
292-8
URL
Read Full Resource

Categories

  • Cost of Disease
  • Economic Burden

Related Facts

  • Medical expenses for Medicare patients with pneumonia higher
    Medicare patients hospitalized for pneumonia have medical expenses—during the hospitalization and for a year afterwards—that are $15,682 higher than in Medicare patients without pneumonia.  
  • 10 most common pathogens leading to HAIs
    The 10 most common pathogens leading to HAIs: Coagulase-negative staphylococci 15% Staphylococcus aureus 15% Enterococcus species 12% Candida species 11% Escherichia coli 10% Pseudomonas aeruginosa 8% Klebsiella pneumoniae 6% Enterobacter species 5% Acinetobacter baumannii 3% Klebsiella oxytoca 2%  
  • Around $35 billion cost to society from antibiotic resistant infections
    The societal costs of antibiotic resistant infections are around $35 billion each year- this includes the cost of lost wages and premature deaths.  
  • >900,000 cases of pneumonia each year
    Each year, more than 900,000 cases of community-acquired pneumonia are estimated to occur in seniors in the U.S.  
  • Drug-resistant MRSA expensive to treat
    As an example, the median treatment cost for drug-resistant MRSA patients over a 6-month period was 118% higher than the cost of treating drug-susceptible MRSA strains.